Target intelligence / Profile preview

Serotonin receptor signaling pathway (None)

Target
None
Molecular classification
GPCR (G protein-coupled receptor), Ion channel (only 5-HT3), Receptor, neurotransmitter receptor pathway
01

Overview

The **serotonin receptor signaling pathway** encompasses the signal-transducing events triggered by serotonin binding to its receptors, which include a diverse group of 14 identified subtypes, grouped into seven major families (5-HT1–7). All but the 5-HT3 subtype are G protein-coupled receptors; 5-HT3 is a ligand-gated ion channel[1][4][5][6]. These receptors mediate diverse physiological effects ranging from neurotransmission, mood regulation, and sleep to cell proliferation and apoptosis[1][3][6]. The pathway is implicated in numerous diseases, including psychiatric disorders, neurodegeneration, and cancer[1][3]. It is commonly targeted by psychotropic drugs, including SSRIs and antipsychotics, which act by modulating receptor activity or serotonin levels[7][3]. Safety concerns include serotonin syndrome and broad systemic side effects resulting from targeting multiple receptors[3][6]. In summary, "Serotonin receptor signaling pathway" is a functional grouping and not an individual canonical molecular target—individual serotonin receptor subtypes are the direct drug targets, not the pathway itself.

Other names
serotonergic signaling pathway5-HT receptor signaling pathwayserotonin-5HT receptor pathway
02

Mechanism of action

Activation/inhibition of GPCR signal transduction; Modulation of ion channel activity (5-HT3 only); Alteration of neurotransmitter release or uptake; Epigenetic enyzmatic modification (serotonylation)

03

Biological functions

Signal transductionNeurotransmissionRegulation of mood, sleep, appetite, body temperatureCell proliferationApoptosisCell migrationEpigenetic regulation via serotonylation
04

Disease associations

Neuropsychiatric disorders (depression, anxiety, schizophrenia, bipolar disorder)CancerEating disorders (e.g., anorexia nervosa)Neurodegenerative diseaseCardiovascular disease
05

Safety considerations

Off-target drug effects due to broad receptor family involvementCardiovascular and metabolic side effectsSerotonin syndrome (when pathway overactivated by drugs)CNS effects (sleep disturbances, mood alterations)
06

Interacting drugs

SSRIs (e.g., fluoxetine)

3 more in the full profile.

Beyond the preview

Go deeper on Serotonin receptor signaling pathway (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serotonin receptor signaling pathway (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call